Treatment News : Still Hoping for a Functionally Cured Canadian Baby

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 16, 2014

Still Hoping for a Functionally Cured Canadian Baby

Despite recent talk that there may be Canadian children who have been functionally cured of HIV just as the famed “Mississippi baby” was, proof of such a feat has not yet materialized, and one of a handful of potential children experienced viral rebound after a recent treatment interruption, MedPage Today reports. At the annual meeting of the Canadian Association for HIV Research, clinicians reported about five children across the country who were all treated with aggressive antiretroviral (ARV) regimens shortly after birth and who afterward showed little or no sign of the virus even under highly sensitive tests.

The clinicians for one of the children, who is now 3 years old, decided to take the child off ARVs at least temporarily because the toddler’s caregiver was not properly adhering to the schedule for administering the ARVs. Before the treatment interruption, the child had undetectable proviral DNA and evidence of cell-associated RNA, although the researchers could not isolate any virus from the child that proved able to replicate. Within two weeks of the treatment interruption, the child’s viral load shot up to 7,797, and after another two weeks to 11,358.

The researchers theorize that one possibility is that, because the child’s mother had resistance to the non-nucleoside reverse transcriptase inhibitor class of ARVs, and because the child was given the NNRTI Viramune (nevirapine) until a switch was made 25 days after birth, a window may have been created that allowed time for the virus to establish a reservoir.

The remaining four children are between 3 and 8 years old and are all on ARVs. Ethical considerations make it difficult to opt to interrupt their treatment, although the potential benefit of helping the children escape side effects from lifetime treatment may weigh in the favor of exploring this option.

To read the MedPage Today story, click here.

Search: Canada, Mississippi baby, functional cure, newborn, HIV, Viramune, nevirapine, Canadian Association for HIV Research.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.